Advances in preclinical hematopoietic stem cell models and possible implications for improving therapeutic transplantation
Autor: | Maria Feliz Norberto, Kathryn S. Potts, Teresa V. Bowman, Bianca A. Ulloa, Ellen Fraint |
---|---|
Rok vydání: | 2020 |
Předmět: |
Primates
0301 basic medicine graft‐vs‐host disease Transplantation Conditioning medicine.medical_treatment ved/biology.organism_classification_rank.species Graft vs Host Disease Disease Hematopoietic stem cell transplantation Bioinformatics Mice 03 medical and health sciences lineage tracing 0302 clinical medicine Tissue‐specific Progenitor and Stem Cells Cell dose Animals Medicine lcsh:QH573-671 Model organism Zebrafish lcsh:R5-920 Concise Review lcsh:Cytology business.industry ved/biology Hematopoietic Stem Cell Transplantation Hematopoietic stem cell Cell Biology General Medicine preclinical models hematopoietic stem cells Transplantation Disease Models Animal surgical procedures operative 030104 developmental biology medicine.anatomical_structure Stem cell lcsh:Medicine (General) business 030217 neurology & neurosurgery Ex vivo transplantation Developmental Biology |
Zdroj: | Stem Cells Translational Medicine, Vol 10, Iss 3, Pp 337-345 (2021) Stem Cells Translational Medicine |
ISSN: | 2157-6580 2157-6564 |
Popis: | Hematopoietic stem cell transplantation (HSCT) is a treatment for many malignant, congenital, and acquired hematologic diseases. Some outstanding challenges in the HSCT field include the paucity of immunologically‐matched donors, our inability to effectively expand hematopoeitic stem cells (HSCs) ex vivo, and the high infection risk during engraftment. Scientists are striving to develop protocols to generate, expand, and maintain HSCs ex vivo, however these are not yet ready for clinical application. Given these problems, advancing our understanding of HSC specification, regulation, and differentiation in preclinical models is essential to improve the therapeutic utility of HSCT. In this review, we link biomedical researchers and transplantation clinicians by discussing the potential therapeutic implications of recent fundamental HSC research in model organisms. We consider deficiencies in current HSCT practice, such as problems achieving adequate cell dose for successful and rapid engraftment, immense inflammatory cascade activation after myeloablation, and graft‐vs‐host disease. Furthermore, we discuss recent advances in the field of HSC biology and transplantation made in preclinical models of zebrafish, mouse, and nonhuman primates that could inform emerging practice for clinical application. Clinical (established) and preclinical (theoretical) advances are informing treatment options for circumventing current hematopoietic stem cell transplantation (HSCT) limitations including post‐transplant infection, low HSC donor supply, inflammation, and graft‐vs‐host disease (GVHD). This review covers the advances in preclinical hematopoietic stem cell models and possible implications for improving therapeutic transplantation. |
Databáze: | OpenAIRE |
Externí odkaz: |